Creative Planning’s Clovis Oncology, Inc. CLVS Stock Holding History

Creative Planning’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,500	Closed	-$24K	–	3987
2017 Q2	$24K	Buy	+2,500	New	+$153K	﹤0.01%	3063

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Creative Planning's CLVS Position: Q2 2022 in Review

Creative Planning sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 107,645 shares — an estimated $217K sold.

Creative Planning first reported a position in CLVS in Q2 2014 and held it in 22 quarters. The position peaked at $5.34M in Q3 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Creative Planning reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Creative Planning sold 107,645 Clovis Oncology, Inc. shares in Q2 2022, an estimated $217K.
Creative Planning first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 22 quarters.
Creative Planning's Clovis Oncology, Inc. position peaked at $5.34M in Q3 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Creative Planning's 13F filing for Q2 2022, filed 15 Aug 2022.